Navigation Links
Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland
Date:5/23/2013

WASHINGTON, May 23, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that the company has been named the 2013 Life Science Firm of the Year by the Tech Council of Maryland (TCM).  Vanda was honored at the TCM's 25th Annual Tech Awards Celebration held in Bethesda, Maryland.  The Tech Awards Celebration recognizes the leaders and innovators in the technology and life science communities in Maryland and the surrounding regions.

"We are deeply honored to receive this recognition from the Tech Council of Maryland," said Mihael H. Polymeropoulos , M.D., President and CEO of Vanda.  "We are privileged to work in a region that is supportive of our efforts to develop new treatments designed to improve the lives of others."

In selecting Vanda for this award, the TCM recognized Vanda's commitment to address patient needs and the company's work to develop tasimelteon, a circadian regulator, for the treatment of Non-24-Hour Disorder (Non-24).  Vanda recently announced positive results in the SET and RESET Phase III efficacy studies for Non-24.  Non-24 is a serious, rare circadian rhythm disorder that affects a majority of totally blind individuals.  Currently no treatment for Non-24 has been approved by the U.S. Food and Drug Administration (FDA).  Vanda is targeting a New Drug Application submission with the FDA for tasimelteon in mid-2013.

About The Tech Council of Maryland  
The Tech Council of Maryland (TCM) is the largest technology trade group serving the advanced technology and biotechnology communities of Maryland.  TCM's mission is to advocate for the interests of the technology community, further the role of technology in the Maryland economy, and nurture an environment where technology companies can collaborate, grow and succeed.  For more information, visit www.techcouncilmd.com.  

About Vanda Pharmaceuticals Inc.  
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders.  For more on Vanda, please visit www.vandapharma.com.   

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Various statements in this release are "forward-looking statements" under the securities laws.  Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf.  The information in this release is provided only as of the date of this release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Company Contact:
Jim Kelly 
Senior Vice President and Chief Financial Officer 
Vanda Pharmaceuticals Inc.
(202) 734-3428
jim.kelly@vandapharma.com


'/>"/>
SOURCE Vanda Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Vanda Pharmaceuticals to Announce First Quarter 2013 Financial Results on May 9, 2013
2. Vanda Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference
3. Vanda Reports Successful Completion Of Pre-NDA Meeting With FDA On Tasimelteon For The Treatment Of Non-24-Hour Disorder In The Totally Blind
4. Vanda Pharmaceuticals to Present at the Cowen and Company 33rd Annual Health Care Conference
5. Vanda Pharmaceuticals Reports Fourth Quarter 2012 and Full Year 2012 Results
6. Vanda Announces Phase IIb/III Clinical Study In Major Depressive Disorder Did Not Meet The Primary Endpoint
7. Vanda Announces Positive Results in the Second Phase III Study (RESET) of Tasimelteon for the Treatment of Non-24-Hour Disorder
8. Vanda Pharmaceuticals to Announce Fourth Quarter 2012 Financial Results on February 12, 2013
9. Vanda Pharmaceuticals Reports Third Quarter 2012 Results
10. Vanda Pharmaceuticals to Participate in Two September Healthcare Investor Conferences
11. Vanda Pharmaceuticals to Announce Second Quarter 2012 Financial Results on August 2, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)... May 22, 2017  As the specialty pharmacy ... continue to make the revolutionary shift from volume-based ... for ensuring positive patient outcomes and shaping the ... shifting focus away from clinical trials and toward ... long-term specialty drug therapy utilization in precise patient ...
(Date:5/15/2017)... Enterin Inc., a privately-held CNS pharmaceutical company based ... to treat Parkinson,s disease (PD), has enrolled the first patient ... randomized, controlled, multicenter study involving patients with PD and taking ... over a 9-to-12-month period. The first stage is open label ... Participating sites include Denver , ...
(Date:5/10/2017)... , May 10, 2017 Global Health ... Latin America , published its 2017 ranking ... ranking is based on extensive data analysis from GHI,s ... largest hospitals database for the region. The GHI database covers ... , offering more than 130 data points for each institution ...
Breaking Medicine Technology:
(Date:5/26/2017)... ... , ... “When the Stars Lead Home”: a poignant story of loss, determination, ... Weigel Douglas, an avid reader who lives in the Pacific Northwest with her husband, ... Hills Adventure Camp. She couldn’t be more grateful. , Twelve-year old Tizzy could not ...
(Date:5/26/2017)... ... May 26, 2017 , ... “Cactus Jack: Against All ... so many others. “Cactus Jack: Against All Odds” is the creation of published ... D. Hubbard is married to Jack Carlisle’s third child Jane. Walter. Walter and ...
(Date:5/24/2017)... York (PRWEB) , ... May 24, 2017 , ... Dr. ... vascular surgery in New York City. He is known for his distinguished expertise ... in vascular surgery, Dr. Benvenisty holds sub-specialty training in treating renovascular disease and ...
(Date:5/24/2017)... ... May 24, 2017 , ... Dr. Manju R. Kejriwal, a ... orthodontics, with or without a referral. Dr. Kejriwal understands the emotional and financial ... clear braces in Cincinnati, OH. Patients no longer need to feel the esthetic effects ...
(Date:5/24/2017)... , ... May 24, 2017 , ... ... completed Course II of the HP3 (High-Performance Periodontal Practice) continuing education (CE) series. ... the latest advancements in his field by attending numerous CE courses each year. ...
Breaking Medicine News(10 mins):